T-Cell Prolymphocytic Leukemia: An Overview of Current and Future Approaches.

Publication/Presentation Date

2-9-2021

Abstract

T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell hematologic neoplasm with a very poor prognosis and limited treatment options to date. Single-agent alemtuzumab remains the first line of therapy for the treatment-naive and relapsed/refractory patients. Prospective clinical trials are difficult to conduct given that these patients have a short life expectancy after the initial diagnosis. As a result, researchers are implementing the use of targeted therapies in vitro and ex vivo followed by in vivo trials on a small subset of patients which are reviewed here. Newer approaches in the treatment of T-PLL are developing based on recognizing the cytogenetic phenotype of each patient and targeting the identified defective genes that are usually involved in the cell cycle regulation such as protooncogenes, tumor suppressors, and deoxyribonucleic acid (DNA) repair genes. These could potentially redirect the management in the near future and improve the overall survival (OS) and the progression-free survival (PFS) for these patients.

Volume

13

Issue

2

First Page

13237

Last Page

13237

ISSN

2168-8184

Disciplines

Medicine and Health Sciences

PubMedID

33728186

Department(s)

Department of Medicine

Document Type

Article

Link to Full Text

Share

COinS